聖諾醫藥－Ｂ (2257.HK)

5.890 -0.060 (-1.01%) 市場開市。 截至 03:54PM HKT。

聖諾醫藥－Ｂ

20511 Seneca Meadows Parkway
Suite 200
Germantown, MD 20876
United States
301 740 1730
https://www.sirnaomics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 145

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yang Lu Ph.D.	China Chief Scientific Officer	4.26M	無	1956
Dr. David Mark Evans Ph.D.	Executive Director	2.73M	無	1963
Dr. Xiaochang Dai Ph.D.	Chief Strategy Officer & Executive Director	1.45M	無	1963
Mr. Wing Kei Yip	Group Chief Financial Officer	無	無	1987
Mr. John Buergenthal	Vice President of Human Resources	無	無	無
Dr. Yongxiang Wang	Chief Production Officer	無	無	1952
Dr. Francois J. Lebel FRCPC, M.D.	Chief Medical Officer	無	無	1952
Mr. Ting Cheung Leung CPA	Company Secretary	無	無	1984

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People's Republic of China, and Hong Kong. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat remodeling. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP702 for the treatment of influenza; RIM730 COVID-19 vaccine; and STP122G to treat anticoagulation/thrombosis. In addition, the company is developing STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement-mediated diseases. Sirnaomics Ltd. was founded in 2007 and is headquartered in Germantown, Maryland.

公司管治

截至 無 止，聖諾醫藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。